Abstract
Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Current Pharmaceutical Design
Title:Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants
Volume: 19 Issue: 40
Author(s): Shervin Liddie, Mara A. Balda and Yossef Itzhak
Affiliation:
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Abstract: Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Export Options
About this article
Cite this article as:
Liddie Shervin, Balda A. Mara and Itzhak Yossef, Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/138161281940131209144527
DOI https://dx.doi.org/10.2174/138161281940131209144527 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Chronic HIV-1 Tat and HIV Reduce Rbfox3/NeuN: Evidence for Sex- Related Effects
Current HIV Research Intravitreal Inserts of Steroids to Treat Diabetic Macular Edema
Current Diabetes Reviews Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Liver Growth Factor as a Tissue Regenerating Factor in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Combinatorial Approaches for the Identification of Brain Drug Delivery Targets
Current Pharmaceutical Design Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway
Current Nanoscience Gene Therapy for Ocular Neovascularization
Current Gene Therapy Factors Modulating Chondrogenesis and Mechano-Inductive Systems for Cartilage Tissue Engineering from Mesenchymal Stem Cells: A Review
Current Tissue Engineering (Discontinued) Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Acute Kidney Injury after Complex Endovascular Aneurysm Repair
Current Pharmaceutical Design Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Potential Enzymatic Targets in Alzheimer’s: A Comprehensive Review
Current Drug Targets Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Neuronal Nicotinic Receptors and Neuroprotection: Newer Ligands May Help us Understand their Role in Neurodegeneration
Medicinal Chemistry Reviews - Online (Discontinued) Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued)